CEL-SCI Reports 146 Patients Enrolled In Its Phase 3 Immunotherapy Head And Neck Cancer Trial
Published: Feb 27, 2014
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT:CVM) today reported accelerating progress in patient enrollment in the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). Approximately 146 patients have been enrolled in the Phase III study to date.
Help employers find you! Check out all the jobs and post your resume.